Tumor Models Archives - Page 4 of 10

Clinical Drug Resistant PDX Models

An inevitable challenge emerges over time as tumors develop drug resistance, resulting in treatment failure. The development of targeted therapies...

OncoWuXi Express: Efficacy of DLL3 CAR-T in SHP-77 Tumor Models

OncoWuXi Express: Evaluation of DLL3 CAR-T in SHP-77-Luc Tumor Models Introduction: OncoWuXi Express will continue to keep you informed about...

Combating Drug Resistance in Cancer Therapy

An inevitable challenge emerges over time as tumors develop drug resistance, resulting in treatment failure. This resistance is inherent to...

OncoWuXi Express: Paclitaxel-Induced Resistant Tumor Models

Introduction： OncoWuXi Express will continue to keep you informed about updates to our online tumor model database (OncoWuXi Database), as...

Expanded Role of PDX Models in Anticancer Drug Development

Expanded Role of PDX Models in Anticancer Drug Development Patient-derived xenograft (PDX) models are established by implanting surgically resected patient...

Unveiling Mechanisms of CDK4-CDK6 Inhibitor Resistance in Breast Cancer Models

Cyclin-dependent kinases (CDKs) and their cyclin regulatory subunits form complexes that are essential for driving abnormal growth processes in cancer...

Targeted Protein Degradation of Mutant ER-alpha

Estrogen receptor α (ERα) is considered the main driver in more than 70% of all breast cancers, making this transcription...

siRNA Efficacy in a Xenograft Tumor Model

Protein kinase N3 (PKN3) is a serine/threonine kinase implicated in tumor progression across multiple cancer types. PKN3 mRNA is almost undetectable in normal adult...

Paclitaxel-Resistant Tumor Models

Despite the excellent clinical response to paclitaxel therapy, drug resistance inevitably develops in subsequent treatments. The mechanisms for resistance to...

Knowledge Library